Standard BioTools Overview
Latest ROE for Standard BioTools: 15.72% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow15.72%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, LAB shows a ROE of 15.72%. That is below the Healthcare sector average of 21.28%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.28%. Standard BioTools is at 15.72%, which is lower that average. That is roughly 26.1% below the sector mean. Use the comparison chart on this page to see how LAB stacks up against individual peers as well.
Check the historical chart to see whether LAB's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Standard BioTools with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Standard BioTools's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 15.72%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.28%, while LAB is at 15.72%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
